A retrospective study to investigate risk factors and predictors for immune related adverse events in lung cancer and melanoma treated with Immune checkpoint inhibitors
Latest Information Update: 17 Jun 2020
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Lung cancer; Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 17 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology